Peter MacCallum Cancer Centre welcomes the Therapeutic Goods Administration (TGA) announcement that Novartis Kymriah® (tisagenlecleucel, formerly CTL019) has been approved for treating two aggressive blood cancers.
Professors John Seymour, Mark Dawson and Sarah-Jane Dawson, and Dr Piers Blombery, spoke as presenting authors at the ASH annual scientific meeting in San Diego recently. Attendees learned the latest about their discoveries and successful clinical trials at Peter Mac. These presentations were among a total of 40 papers delivered with Haematology staff as contributing authors, including 16 oral presentations.
In a Victorian first, Peter Mac is expanding its services to patients at the Albury-Wodonga Regional Cancer Centre and Bendigo Health, with new initiatives combining world-class research and remote delivery of clinical trials.
Surgery is a central tenet of cancer care, with around 60% of cancer patients requiring this as part of their treatment. Peter Mac's Professor Bernhard Riedel will lead an international study that will determine if the type of anaesthetic used in cancer surgery affects patient recovery and survival rates.
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.